Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. develops precision therapies for solid tumors designed to preserve organ function. The clinical-stage biotechnology company’s recurring updates center on bel-sar (AU-011), its lead candidate in late-stage development for early choroidal melanoma and in early-stage development for other ocular oncology indications and bladder cancer.
Company news also covers financial results, clinical-program business highlights, investor conference participation, executive leadership changes, and capital actions involving common stock and pre-funded warrants. Aura’s disclosures frequently connect pipeline progress with oncology indications, trial activity, liquidity planning, and governance developments.
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, will have CEO Elisabet de los Pinos participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 8:40 a.m. ET. The discussion will be accessible via a live webcast on the company's Investors & Media page, with a replay available for 90 days. Aura is focusing on developing its lead therapy AU-011 for ocular cancers, including a Phase 2 trial for choroidal melanoma.
Aura Biosciences Inc. (NASDAQ: AURA) announced its financial results for Q3 2021, reporting a net loss of $8.8 million compared to $3.6 million in Q3 2020. The company successfully completed a public offering, raising approximately $86.9 million to support the development of its lead therapy, AU-011, for choroidal melanoma. Significant data from Phase 1b/2 trials highlighted a tumor growth reduction of 0.483 mm/year and a 64% tumor control rate. Aura plans to initiate pivotal programs in 2022 and expand its oncology pipeline into non-muscle invasive bladder cancer.
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company, will have CEO Elisabet de los Pinos participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx conference on November 30, 2021, at 2:15 p.m. ET. This event will showcase Aura’s innovative virus-like drug conjugate (VDC) therapies targeting ocular and urologic cancers. A live webcast will be available on the company’s website, with an archived replay for 90 days post-event. Aura aims to revolutionize cancer treatment, focusing initially on ocular oncology with promising data from its lead product candidate, AU-011.
Aura Biosciences presented critical data on AU-011, its virus-like drug conjugate for treating choroidal melanoma, at the AAO 2021 Annual Meeting. The Phase 1b/2 trial showed a statistically significant tumor growth reduction of -0.483 mm/year (p = 0.018) and a 64% tumor control rate among 14 patients. Visual acuity preservation was achieved in 71% of cases. Furthermore, preliminary findings from the ongoing Phase 2 trial with suprachoroidal administration reported no serious adverse events. These results underscore AU-011’s potential as a safe first-line therapy for this aggressive cancer.
Aura Biosciences, a clinical-stage oncology firm, has priced its initial public offering (IPO) at $14.00 per share for 5,400,000 shares, aiming to raise approximately $75.6 million. The offering is scheduled to begin trading on the Nasdaq Global Market under the ticker AURA on October 29, 2021, with the closing date set for November 2, 2021. Aura has also granted underwriters a 30-day option for an additional 810,000 shares. The funds will support the development of its innovative virus-like drug conjugate therapies for various cancer indications.